Table 3 Baseline demographic and clinical characteristics of the participants in the MATCH study
Characteristics | All patients | Single-disciplinary cohort (2011.08–2021.04) | Multidisciplinary cohort (2018.06–2021.04) | P value |
|---|---|---|---|---|
No. of patients | N = 3241 | N = 2741 | N = 500 |  |
Ethnicity, male, n (%) | 1911 (59.0) | 1624 (59.2) | 287 (57.4) | 0.440 |
Age (years), mean ± SD | 28.4 ± 14.6 | 28.3 ± 14.4 | 29.4 ± 15.6 | 0.118 |
Race, Han, n (%) | 3109 (95.9) | 2629 (95.9) | 480 (96.0) | 0.929 |
Onset manifestation | ||||
 Hemorrhage, n (%) | 1984 (61.2) | 1677 (61.1) | 307 (61.4) | 0.927 |
 Seizure, n (%) | 754 (23.3) | 647 (23.6) | 107 (21.4) | 0.283 |
 Headache, n (%) | 698 (21.5) | 587 (21.4) | 111 (22.2) | 0.695 |
 Neurofunctional deficit, n (%) | 583 (18.0) | 488 (17.8) | 95 (19.0) | 0.522 |
 Others, n (%) | 271 (8.4) | 230 (8.4) | 42 (8.4) | 0.995 |
Frequency of hemorrhage before admission, n | 2268 | 1917 | 351 | 0.906 |
Type of seizure, generalized, n (%) | 629 (19.3) | 542 (19.7) | 87 (17.4) | 0.217 |
Duration from diagnosis to treatment (months), median, IQR | 2.9 (0.9, 12.8) | 2.8 (0.9, 12.9) | 3.0 (0.9, 12.6) | 0.471 |
Admission mRS, median, IQR | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 0.653 |
Type of treatment | ||||
 Conservation, n (%) | 491 (15.1) | 412 (15.0) | 79 (15.8) | 0.659 |
 Microsurgery, n (%) | 1158 (35.7) | 991 (36.2) | 167 (33.4) | 0.237 |
 Embolization, n (%) | 412 (12.7) | 346 (12.6) | 66 (13.2) | 0.722 |
 SRS, n (%) | 480 (14.8) | 413 (15.1) | 67 (13.4) | 0.334 |
 Hybrid surgery, n (%) | 141 (4.4) | 120 (4.4) | 21 (4.2) | 0.858 |
 Staged embolization + Microsurgery, n (%) | 83 (2.6) | 67 (2.4) | 16 (3.2) | 0.325 |
 Embolization + SRS, n (%) | 381 (11.8) | 312 (11.4) | 69 (13.8) | 0.123 |
 Microsurgery + SRS, n (%) | 45 (1.4) | 39 (1.4) | 6 (1.2) | 0.695 |
 Microsurgery + Embolization + SRS, n (%) | 50 (1.5) | 41 (1.5) | 9 (1.8) | 0.612 |
Follow-up duration (years), median, IQR | 5.6 (3.4, 7.9) | 6.3 (4.4, 8.3) | 2.4 (1.8, 3.3) |  < 0.001* |
 Lost follow-up, n (%) | 253 (7.8) | 204 (7.4) | 49 (9.8) | 0.071 |
Patients who have completed 3 years follow-up, n (%) | 2372 (79.4) | 2181 (86.0) | 191 (42.4) |  < 0.001* |